News blog
CustomVis
- BY: Andrew Hore |
- POSTED: 06/11/2009 |
CustomVis has gained Australian regulatory approval for its presbyopia treatment.
The laser eye surgery technology developer gained approval from the Therapeutic Goods Administration in Australia to add to its European CE approval. The PresBvis treatment can be administered by the existing installed base of Pulzar Z1 lasers. CustomVis will generate a fee for each patient treated.
Presbyopia is an age-associated progressive loss of the focusing power of the eye’s lens, making it difficult to see objects close-up. Most people over 40 years old suffer from this. PresBvis can restore close-up vision without harming long distance sight.
At 1.3p a share, up 0.2p on the day, CustomVis is valued at £2.5m.
Bob Morton’s Hawk Investment Holdings bought more shares in the recent placing at 1.3p a share and holds 23.5% of CustomVis.
© 2026 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
- Browse by issue
- All issues
- Popular tags
- All tags
- AIM Micro feeds
Keep up to date with articles published at AIMMicro.com. Subscribe to AIM Micro RSS Feeds
|